Patient-specific, integrated risk-based application of all-HSCT in AML in first CR
The proposed patient-specific application of allo-HSCT in patients with AML in their first CR integrates the individual risks for relapse and nonrelapse mortality and aims for a DFS benefit of at least 10% for the individual patient compared with consolidation by a non-allo-HSCT approach. Used with permission from Cornelissen et al.37
DFS indicates disease-free survival; EVI1, Ecotropic viral integration site 1; CEBPA, gene encoding CCAAT enhancer-binding protein α; FLT3, gene encoding fms-like tyrosine kinase receptor-3; N/A, not advocated; NPM1, gene encoding nuclear matrix protein; and MRD, minimal residual disease.
*The categorization of AML is based on cytogenetic, molecular, and clinical parameters (including WBC) into good, intermediate, and (very) poor subcategories and is subject to continuing study and debate. Here, categories are arbitrarily presented according to the latest policy of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) consortium. Relapse percentages were derived from published reports.
†Includes response to first induction. Categorization requires one of the parameters indicated.
